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Abstract: Tyrosinase-related protein 1 (TYRP1) is one of the three human melanogenic enzymes
involved in the biosynthesis of melanin, a pigment responsible for the color of the skin, hair, and eyes.
It shares high sequence identity with tyrosinase, but has two zinc ions in its active site rather than two
copper ions as in tyrosinase. Typical tyrosinase inhibitors do not directly coordinate to the zinc ions of
TYRP1. Here, we show, from an X-ray crystal structure determination, that phenylthiourea, a highly
potent tyrosinase inhibitor, does neither coordinate the active site zinc ions, but binds differently from
other structurally characterized TYRP1-inhibitor complexes. Its aromatic ring is directed outwards
from the active site, apparently as a result from the absence of polar oxygen substituents that can
take the position of water molecules bound in the active site. The compound binds via hydrophobic
interactions, thereby blocking substrate access to the active site.
Keywords: human tyrosinase; human tyrosinase-related protein; phenylthiourea; inhibitor; crystal
structure; N-glycosylation; albinism; melanogenesis; zinc–copper enzymes
1. Introduction
The human melanogenic enzymes tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1),
and tyrosinase-related protein 2 (TYRP2) take part in the biosynthesis of melanin, a pigment that is
responsible for the color of the skin, hair, and eyes [1]. Mutations of the genes that code for these
proteins may lead to loss of skin pigmentation, which in turn has been linked to an increased incidence
of carcinoma [2]. In addition, loss of melanin is often (but not always) associated with abnormal
development of the retina, which causes severe visual defects [3]. The precise relation between melanin
biosynthesis and eye development has not yet been established, although the tyrosine hydroxylation
product L-3,4-dihydroxyphenylalanine (L-DOPA) has been hypothesized to serve as the link [3].
Although the role of TYR in the melanin biosynthetic pathway is generally accepted, the function
of TYRP1 is less clear [1]. The crystal structure of the intra-melanosomal domain of TYRP1 showed
that the active site contains two zinc ions, bound virtually indistinguishably from the binuclear type
3 copper site of bacterial and fungal tyrosinases [4]. Because zinc ions, in contrast to copper ions, are not
redox-active, this implies that TYRP1 must have a different activity from TYR, as indeed corroborated
experimentally [4]. In this respect, the 5,6-dihydroxyindole-2-carboxylic acid (DHICA) oxidase activity
of the recombinant melanosomal domain of human TYRP1, reported recently [5], may result from the
presence of (trace amounts of) copper ions, and further research is needed to establish the physiological
significance of this observation.
Binding of L-tyrosine and the L-DOPA analogue L-mimosine to TYRP1 showed that these
compounds do not directly interact with the zinc ions of TYRP1, in contrast to, for example,
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the tyrosine analogue tyrosol, which directly coordinates Cu-A in B. megaterium tyrosinase [6]. To further
investigate the binding of inhibitors to melanogenic enzymes, we determined the interaction of TYRP1
with the inhibitor phenylthiourea (PTU), the most potent inhibitor of human TYR that we tested.
To reduce any effect of amino acid differences, we used a TYRP1 triple mutant (TYRP1-3M) in
which the three non-conserved active site residues were replaced by the corresponding ones of TYR
(Y362F/R374S/T391V). The activity of this triple mutant is similar to that of native TYRP1, both in
the Zn- and Cu-substituted forms; replacing the zinc ions by copper ions confers DHICA oxidase
activity to both TYRP1 and the 3M mutant [4]. Our results show that PTU does not coordinate the
active site zinc ions, but has a very different binding mode compared to the other tyrosinase inhibitors
bound to TYRP1. Most conspicuously, the aromatic ring of PTU is directed outwards from the active
site, which appears to result from the absence of polar oxygen substituents that can take the position
of water molecules bound in the active site. The compound binds via hydrophobic interactions,
thereby blocking substrate access to the active site.
TYR, TYRP1, and TYRP2 not only differ in their enzymatic activity, but also in their N-glycosylation
patterns. Three N-glycosylation sequons (Asn86, Asn290, Asn371 (TYR sequence numbering)) are
conserved in the human melanogenic enzymes. No disease-related mutations are known for TYR Asn86
and Asn290, suggesting that glycosylation of these sites is not essential for functionality. In contrast,
Asn371 mutations have been found in patients with classic tyrosinase-dependent oculocutaneous
albinism. Asn371 is located at the rim of the entrance to the active site pocket, about 15–20 Å from the
TYR copper ions, suggesting that the absence of glycosylation at this site severely compromises the
enzyme’s activity, or stability, or both.
2. Results
2.1. Inhibition of Human TYR by Phenylthiourea (PTU)
Various compounds with well-known reductive tyrosinase activity were tested in an on-plate
colorimetric assay for their potency against the melanosomal domain of TYR. Interestingly,
these experiments demonstrated that PTU is the most potent inhibitor of human tyrosinase (Figure 1),
similar to previous studies with mushroom tyrosinase [7]. PTU has been suggested to adopt an unusual
bridging binding mode when interacting with a binuclear copper(II) center [8]. Moreover, no crystal
structures of tyrosinase with bound PTU are available in the Protein Data Bank (PDB). Therefore, it was
deemed of interest to investigate the structural details of the interaction of PTU with TYRP1-3M,
a triple mutant of TYRP1 in which the three non-conserved active site residues were replaced by the
corresponding ones of TYR (Y362F/R374S/T391V) [4].
Figure 1. Colorimetric tyrosinase activity assay showing the inhibition by different inhibitors.
The images were taken at 3 min (upper panel) and 30 min (lower panel) after the start of the
reaction. The buffer control contained 0.5 mM 3-methyl-2-benzothiazolinone hydrazine hydrochloride
hydrate (MBTH) and 2 mM L-3,4-dihydroxyphenylalanine (L-DOPA) in 40 mM phosphate buffer,
pH 6.5. The other wells contained the buffer control condition with added 0.4 µM tyrosinase (TYR)
protein and 2 mM inhibitor, as indicated in the figure. PTU: phenylthiourea.
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2.2. Interaction of Phenylthiourea (PTU) with TYRP1-3M
The crystal structure of TYRP1-3M with bound PTU was elucidated at 2.2 Å resolution (Figure 2;
Table 1). The crystal was formed with four molecules in the asymmetric unit (chains A, B, C, and D)
(Figure 2), identical to native TYRP1 [4]. The PTU aromatic ring pointed outwards from the binuclear
zinc site; its position was stabilized by hydrophobic interactions with the side chains of Phe362, Leu382,
and Val391 (Figure 2). The thiourea amino group was hydrogen bonded to the backbone oxygen of
Gly389 and a water molecule (W4), whereas the amide nitrogen and thiourea sulfur had hydrogen
bonds with water molecules W3 and W2, respectively (Figure 2). Surprisingly, PTU did not interact
with the binuclear metal site, but blocked substrate access to the active site. All interactions that
stabilized PTU in TYRP1-3M were conserved in the TYR active site, which suggests that PTU can bind
in a similar way to native TYR.
Figure 2. Tyrosinase-related protein 1 triple mutant (TYRP1-3M) with PTU bound in the active site.
The TYRP1-3M crystal contained four molecules in the asymmetric unit (chains A, B, C, and D);
N-linked sugars are shown as sticks in magenta; PTU from chain A is shown as sticks in blue at the
active site. The details of the PTU interaction network in the active site is shown in the blow-up; W1,
W2, W3, and W4 correspond to water molecules 15, 9, 331, and 356, respectively, in Protein Data Bank
(PDB) 5M8S. PTU is mainly stabilized by hydrophobic interactions with the protein. The three residues
mutated in the 3M mutant are shown in gold (F362, S374, V391).
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Table 1. Statistics of data collection and refinement.
Data Collection TYRP1-3M_PTU
Space group P212121
Cell dimensions, a, b, c (Å) 90.1, 141.8, 191.7
Cell dimensions, α, β, γ (◦) 90.0, 90.0, 90.0
Resolution 48.92–2.2 (2.32–2.2) 1
Rmerge (%) 10.3 (84.7) 1
I/σI 10.0 (1.4) 1
Completeness (%) 99.4 (99.3) 1
Redundancy 4.0 (3.6) 1
Refinement
Resolution (Å) 48.92–2.2
No. of reflections 124,119
Rwork/Rfree (%) 19.36/23.49
No. of atoms
Protein 14,216
Water molecules 722
Carbohydrate 635
Zinc ions 9
Ligand 40
B factors (Å2)
Protein 43.485
Water 45.518
Carbohydrate 60.677
Zn 33.896
Ligand 40.008
R.M.S. deviations
Bond lengths (Å) 0.009
Bond angles (◦) 1.220
PDB entry 5M8S
1 Data between parentheses are for the highest resolution shell.
Superimposition of the PTU-inhibited TYRP1-3M structure and TYRP1-3M structures with bound
kojic acid, mimosine, and tropolone (PDB entries 5M8Q, 5M8R, and 5M8T, respectively [4]) revealed
that PTU binds very differently from these compounds (Figure 3). Most conspicuously, the aromatic
ring of PTU was directed outwards from the active site, whereas the other inhibitors had their ring
system oriented towards the binuclear metal-binding site. The amide nitrogen (Figure 3B, annotated
as N*) of PTU perfectly superimposed on the ring C5 carbon atom of kojic acid, the ring nitrogen
atom of mimosine, and the Cα5 carbon atom of tropolone (Figure 3). The space occupied by water
molecules W2 and W3 in the PTU-bound structure was taken by the ring oxygen atoms of kojic acid,
mimosine, and tropolone. These oxygen atoms were hydrogen bonded to the bridging water molecule
W1 between the two metal ions in the active site (Figure 3). The PTU sulfur atom coincided with a
ring carbon atom of the inhibitors (e.g., the Cε atom of the mimosine ring). Thus, it appeared that the
different binding mode of PTU originated from the absence of polar oxygen substituents that could
take the position of bound water molecules in the active site.
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Figure 3. PTU binds in the active site of TYRP1-3M with its aromatic ring pointing outwards from
the binuclear metal center, whereas the other inhibitors point inwards. (A) Binding of the L-DOPA
analogue mimosine (cartoon atoms colored in light pink; PDB 5M8R); N* indicates the position of
the nitrogen atom in the aromatic ring of mimosine. (B) Superimposition of TYRP1-3M with bound
mimosine (MIM, light pink; PDB 5M8R), tropolone (TPL, light blue; PDB 5M8T), kojic acid (KOJ, gray;
PDB 5M8Q), and PTU (PTU, green; PDB 5M8S). MIM, TPL, and KOJ bind with their aromatic ring
pointing inwards, towards the binuclear metal site. PTU binds outward with its aromatic ring. In the
figure, oxygen atoms are colored in red, and nitrogen atoms in blue; zinc atoms are labeled as ZNA and
ZNB; W1 is the bridging water molecule between ZnA and ZnB.
3. Discussion
The precise function and activity of TYRP1 has been puzzling [1,4]. Initial reports suggested
that TYRP1 exhibits tyrosine hydroxylase, L-DOPA oxidase, dopachrome tautomerase, or DHICA
(5,6-dihydroxyindole-2-carboxylic acid) oxidase activity [9–11]. However, purified recombinant
intra-melanosomal human TYRP1 expressed in insect cells neither showed hydroxylase activity nor
oxidase activity [4]. Unfortunately, dopachrome tautomerase activity could not be evaluated because of
unavailability of suitable substrates. The absence of hydroxylase and oxidase activity is not surprising
in light of the presence of two redox-inactive zinc ions instead of copper ions, as observed in the
active site of tyrosinases. Yet, TYRP1 does bind typical tyrosinase substrates and inhibitors such
as tyrosine, mimosine, kojic acid, and tropolone [4]. These compounds bind via aromatic stacking
interactions with H381, and hydrogen bonding with S394, but they do not directly interact with the
zinc ions. The aromatic hydroxy and keto-groups of tyrosine and the L-DOPA analogue L-mimosine
are hydrogen-bonded to the water molecule, bridging the two zinc ions [4].
Of the various inhibitors we tested, phenylthiourea (PTU) was the most potent inhibitor of human
tyrosinase (Figure 1). It binds to TYRP1 with its aromatic ring pointing outwards from the active
site, blocking the entrance to the active site. The thiourea group did not interact with the binuclear
metal site. In contrast, in Ipomoea batatas catechol oxidase (PDB entry 1BUG, [12]), another binuclear
copper-containing enzyme with a very similar fold to tyrosinase, the PTU phenyl ring, occupied
the same position as in TYRP1, but the thiourea sulfur atom was inserted between the two active
site copper ions, coordinating both of them. One conspicuous difference between the two enzymes,
besides the nature of the active site metal ions, was the presence of a Phe residue instead of a Val
residue at position 391 (TYRP1 numbering). In catechol oxidase, the Phe residue provided stabilizing
edge-to-face aromatic interactions with the phenyl ring of PTU, which cannot be given by Val.
An important question is whether the nature of the bound metal ions in the active site (copper in
TYR, but zinc in TYRP1) affects the binding mode of PTU. The ionic radii of Cu2+ and Zn2+ ions
are very similar (0.73 and 0.74 Å for Cu2+ and Zn2+, respectively [13]) and also their charge is the
same. Comparing the binuclear zinc-binding site of TYRP1 with the binuclear copper-binding sites of
tyrosinases, no differences in coordination geometry were observed. Of course, during the reaction
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catalyzed by tyrosinases, the copper ions switched between the Cu2+ and Cu1+ states, and this
may have affected the affinity for and binding mode of PTU. However, with the currently available
evidence, it appears that PTU was bound by hydrophobic interactions at the entrance of the active
site, blocking access to the enzyme. In catechol oxidase, a nearby Phe side chain provided stabilizing
edge-to-face aromatic interactions with the phenyl ring of PTU, thus allowing PTU to bind more deeply
into the active site.
Superimposing the TYRP1-3M PTU structure on the human TYR model (see the Materials and
Methods section and [1]) shows that PTU can be accommodated in the same position and orientation in
the TYR active site as observed in TYRP1-3M. The strong inhibition by PTU also indicates that recognition
of the substrate’s carboxylate group and interaction with any “substrate-guiding residues” in the
second shell of the active site appears not to be essential [13]. Finally, the binding mode of PTU suggests
that new types of inhibitors could be generated by replacing the PTU thiourea sulfur and nitrogen
atoms, or the mimosine amino and carboxylate groups with an aromatic ring. Two similar aromatic
ring-containing inhibitors have been reported for tyrosinase, viz., deoxyarbutin [14] and lucidone [15].
Thus, our crystal structure of PTU-inhibited TYRP1-3M enabled us to identify key residues in substrate
binding, and provides a platform to design novel compounds targeting melanogenic proteins.
A further important question is whether differences in glycosylation may have consequences for
activity. As summarized in Figure 4, the mammalian TYR, TYRP1, and TYRP2 proteins have distinct
N-glycosylation patterns. For instance, all analyzed mammalian tyrosinases have N-glycosylation
sites at Asn86, Asn111, Asn161, Asn230, Asn290, Asn337, and Asn 371 (human tyrosinase sequence
numbering). In total, 13 distinct N-glycosylation positions are present in the three melanogenic enzymes,
but none of them were fully conserved in all analyzed sequences (Figure 4). All N-glycosylation sites
are on the surface of the protein models and fully accessible (Figure 5).
Figure 4. N-glycosylation sites in mammalian melanogenic enzymes. Indicated are the sequence
positions of Asn residues that are part of N-X-S/T N-glycosylation sequence motifs in human, mouse,
rabbit, and rat TYR, TYRP1, and TYRP2. Thirteen different putative N-glycosylation sites are present.
The residue numbering is according to the sequence numbering of human TYR, human TYRP1,
and human TYRP2, respectively. The sequences of human, mouse, rabbit, and rat TYR, TYRP1,
and TYRP2 were retrieved from the UniProtKB protein knowledgebase (www.uniprot.org), with entry
numbers P14679 (human TYR), P11344 (mouse TYR), G1SYA0 (rabbit TYR), D4A9G4 (rat TYR),
P17643 (human TYRP1), P07147 (mouse TYRP1), G1SLB6 (rabbit TYRP1), D3ZH71 (rat TYRP1),
P40126 (human TYRP2), P29812 (mouse TYRP2), and G1TFA4 (rabbit TYRP2). † Asn92 is not present
in human TYRP2; Asn411 is only present in mouse TYRP2. ¶ Asn304 is not present in mouse and rat
TYRP1; Asn385 is not present in rabbit TYRP1.
A search of the human genomic mutation database [16] revealed that no disease-related mutations
are known for the N-glycosylation sequons of TYR Asn86, Asn111, Asn230, and Asn290, suggesting that
glycosylation of these sites is not essential for functionality. These glycosylation sites are located at
the back of the molecule when looking from the outside into the active site pocket, or behind peptide
chains that prevent the glycan residues coming near the active site (Figure 5). A mutant protein
(called D5 mutant), with these four asparagine residues replaced by Asps (plus an additional Asn337Asp
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mutation), still retained significant specific activity (reduced by only ≈30%) [17]. For Asn161, which
is also located at the back of the protein, also no disease-related mutations are known. Adding the
Asn161Asp mutation to the D5 mutant reduced the specific activity of this D6 mutant only moderately
(by an additional 12%) [17]. This suggests that N-glycosylation at Asn86, Asn111, Asn161, Asn230,
and Asn290 is not crucial for the functionality of human tyrosinase. On the other hand, mutations
of the N-glycosylation sequons of TYR Asn337 and Asn371 have been found in patients with classic
tyrosinase-dependent oculocutaneous albinism [18,19]. These N-glycosylation sites are located at the
rim of the entrance to the active site pocket, about 15–20 Å from the active site copper ions, and the
presence of glycan chains may affect the active site conformation (Figure 5). Although the Asn337Asp
mutation was already included in the D5 mutant described above, adding the Asn371Asp mutation to
the D5+Asn168Asp mutant dramatically reduced the specific activity (to 2% of that of the wild-type
tyrosinase) [17]. This suggests that the Asn371 N-glycosylation site is the most important for the
enzyme’s functionality, whether it be by stabilizing the enzyme, or by a direct effect on its activity, or
by both. Further research is necessary to establish the precise role on Asn371 N-glycosylation.
Figure 5. Location of the N-glycosylation sites in the model of human TYR and the crystal structure of
glycosylated human TYRP1 (PDB 58ML [4]). The Asn residues of the N-glycosylation sequons
(Asn-X-Ser/Thr) (Figure 4) in human TYR (in color) and human TYRP1 (in grey) are labelled.
Glycans observed in the human TYRP1 crystal structure are depicted as sticks. Disease-associated Asn
mutation sites are shown as red surfaces; the other N-glycosylation sites are shown as green surfaces.
The tyrosinase-like domain is shown in blue and the Cys-rich domain in green. Metal ions are shown
as pink spheres and coordinating waters are in red.
4. Materials and Methods
4.1. Protein Expression and Purification
Overexpression and purification of TYR was done according to [20]. TYRP1-3M recombinant
protein was prepared as described previously [4]. In brief, 2 L of sf21 cells were grown to a cell
density of ≈1.0 million cells per mL before being infected with 2 mL recombinant baculovirus solution.
The cells were cultured for 4 more days at 300 K until recombinant protein expression reached a plateau.
The medium was clarified by centrifugation at 6000 g for 30 min and then concentrated to ≈100 mL
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using a 10 kDa cut-off QuixStand Benchtop System (GE Healthcare, Chicago, U.S.A.). The concentrated
medium was incubated with 5 mL of Ni-NTA agarose resin (QIAGEN, Venlo, The Netherlands) for
20 min, which was then applied to a 20 mL gravity flow chromatography column (Econo-Pac column,
Bio-Rad). The flow-through was discarded and the bound protein was washed with 100 mL of wash
buffer (25 mM Tris-HCl, pH 7.8, 150 mM NaCl, 50 mM imidazole) and eluted with 20 mL of elution
buffer (25 mM Tris-HCl, pH 7.8, 150 mM NaCl, 500 mM imidazole). The eluted protein solution was
mixed with home-made TEV protease at a protein to TEV ratio of 50:1 (weight ratio) and dialyzed
overnight at 277 K against dialysis buffer (25 mM Tris-HCl, pH 7.8, and 150 mM NaCl) to remove
the C-terminal 6×His-tag. TEV protease and uncleaved protein were removed by Ni-NTA agarose
(QIAGEN) chromatography. The flow-through containing the cleaved TYRP1-3M protein was collected,
and the buffer was exchanged to ion-exchange buffer (25 mM Tris-HCl, pH 8.8, 50 mM NaCl) using a
PD-10 desalting column (GE Healthcare). The resulting protein solution was then applied to a Mono
Q 5/50 GL column (GE Healthcare) pre-equilibrated with the ion exchange buffer. The flow-through
fractions that contain the pure TYRP1-3M were pooled, concentrated, and then applied to a final gel
filtration chromatography column (Superdex 200 10/300 GL; GE Healthcare) pre-equilibrated with the
crystallization buffer (10 mM Tris-HCl, pH 7.8, 100 mM NaCl). The elution fractions containing the
pure protein were pooled and concentrated using a 30 kDa cut-off Amicon membrane (Merck Millipore,
Burlington, Massachusetts, USA) to a concentration of ≈25 mg/mL, and stored at 193 K.
4.2. Activity Assays
Tyrosine hydroxylase and L-DOPA oxidase activities were determined at pH 6.5 and 298 K,
as previously described [4]. On-plate tyrosinase activity was determined colorimetrically at pH 6.5 and
298 K in a Nunc Edge 96-well plate (Thermo Fisher Scientific, Waltham, Massachusetts, USA), in the
presence of 0.4 µM L-tyrosine as substrate and 2 mM tropolone, 2 mM kojic acid, 2 mM mimosine,
or 2 mM phenylthiourea as TYR inhibitors. Images were taken using a Photo HP Scanjet G3110 scanner
(Hewlett-Packard, Palo Alto, California, USA) after 3 and 30 min.
4.3. Crystallization, Data Collection, and Processing
TYRP1-3M native crystals were generated in a condition containing 0.1 M Tris (pH 7.0), 0.2 M
NaCl, and 30% (w/v) PEG 3000, with a protein to reservoir ratio of 3:1. Rod-like crystals appeared in
2 days and grew to full size in 7 days. For soaking PTU in the crystals, native crystals were fished in a
cryo drop and soaked with reservoir solution supplemented with 20% (v/v) glycerol and saturated
PTU for 5 to 10 min before flash freezing in liquid nitrogen for diffraction experiments.
X-ray diffraction data collection was carried out at the MASSIF-1 automatic beamline of the
European Synchrotron (ESRF), Grenoble, France [21]. The dataset was processed and integrated using
the program XDS [22] in combination with the program SCALA [23] from the CCP4 package [24].
The crystal belongs to P212121 space group. The structure was solved by molecular replacement in
PHASER [25] using TYRP1 (PDB 5M8L) as a search model. The resulting single solution gave four
molecules in the asymmetric unit, with clear difference density for PTU. Manual model rebuilding and
refinement were iteratively performed with COOT [26] and PHENIX [27], respectively. Statistics of
data collection and refinement are summarized in Table 1. Atomic coordinates and structure factor
amplitudes have been deposited with the Protein Data Bank with entry code 5M8S.
4.4. Modeling
The full amino acid sequence of human tyrosinase (Uniprot entry P14679; 529 amino acid residues,
including the N-terminal signal sequence and the C-terminal transmembrane and cytoplasmic domains)
was submitted to the Swiss-model server [28]. Four models were generated by the server on the basis
of the 5M8L (TYRP1 [4]) and 4YD9 (squid hemocyanin [29]) crystal structures present in the Protein
Data Bank. The most complete model was that based on the TYRP1 structure (coverage of residues
19–455; 44.37% sequence identity) compared to coverage of residues 201-452 only in the models based
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on chains B, J, and M of squid hemocyanin (31.68%–33.50% sequence identity). Because 2 close contacts,
10 Ramachandran outliers, and 9 rotamer outliers were present in the TYRP1-based model, the model
was energy-minimized using the Yasara server [30]. One Ramachandran outlier (Asp240) and seven
poor rotamers remained, but several conserved side chains had acquired conformations that differed
significantly from those in the TYRP1 structure. These inconsistencies were manually corrected using
COOT [26], and the resulting model was energy-minimized using the ModRefiner server [31]. The final
model retained one Ramachandran outlier (Ser331), but no poor rotamers. From a comparison of the
various intermediate models, the errors in the modeled Ca positions were estimated to be around 0.5 Å.
Because no 3D-structural information from homologous proteins was available for residues 455-529,
the conformation of these residues was assessed using the PredictProtein [32] and Foldex [33] servers,
as well as the JPRED4 server [34].
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Abbreviations
L-DOPA L-3,4-dihydroxyphenylalanine
MBTH 3-methyl-2-benzothiazolinone hydrazine hydrochloride hydrate
PDB Protein Data Bank (www.rcsb.org)
PTU Phenylthiourea
TYR Tyrosinase
TYRP1 Tyrosinase-related protein 1
TYRP1-3M
Triple (Y362F/R374S/T391V) mutant of TYRP1, with the three non-conserved
active site residues replaced by the corresponding ones of TYR
TYRP2 Tyrosinase-related protein 2
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